117 related articles for article (PubMed ID: 9627060)
1. Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein.
Rauscher FJ; Morris JF; Fredericks WJ; Lopez-Guisa J; Balakrishnan C; Jost M; Herlyn M; Rodeck U
Hybridoma; 1998 Apr; 17(2):191-8. PubMed ID: 9627060
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study.
Charles AK; Mall S; Watson J; Berry PJ
Mol Pathol; 1997 Jun; 50(3):138-44. PubMed ID: 9292148
[TBL] [Abstract][Full Text] [Related]
5. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
7. Expression of WT1 protein in fetal kidneys and Wilms tumors.
Grubb GR; Yun K; Williams BR; Eccles MR; Reeve AE
Lab Invest; 1994 Oct; 71(4):472-9. PubMed ID: 7967503
[TBL] [Abstract][Full Text] [Related]
8. WT1-specific serum antibodies in patients with leukemia.
Gaiger A; Carter L; Greinix H; Carter D; McNeill PD; Houghton RL; Cornellison CD; Vedvick TS; Skeiky YA; Cheever MA
Clin Cancer Res; 2001 Mar; 7(3 Suppl):761s-765s. PubMed ID: 11300470
[TBL] [Abstract][Full Text] [Related]
9. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia.
Menssen HD; Renkl HJ; Rodeck U; Kari C; Schwartz S; Thiel E
Int J Cancer; 1997 Mar; 70(5):518-23. PubMed ID: 9052749
[TBL] [Abstract][Full Text] [Related]
10. Production and characterization of mouse monoclonal antibodies to human zinc finger OZF protein overexpressed in pancreatic carcinomas.
Ferbus D; Antoine K; Goubin G
Hybridoma; 1999 Oct; 18(5):431-6. PubMed ID: 10600030
[TBL] [Abstract][Full Text] [Related]
11. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
Iben S; Royer-Pokora B
Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1.
Lee YI; Kim SJ
DNA Cell Biol; 1996 Feb; 15(2):99-104. PubMed ID: 8634146
[TBL] [Abstract][Full Text] [Related]
13. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product.
Nakagama H; Heinrich G; Pelletier J; Housman DE
Mol Cell Biol; 1995 Mar; 15(3):1489-98. PubMed ID: 7862142
[TBL] [Abstract][Full Text] [Related]
14. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.
Dey BR; Sukhatme VP; Roberts AB; Sporn MB; Rauscher FJ; Kim SJ
Mol Endocrinol; 1994 May; 8(5):595-602. PubMed ID: 8058069
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of the Wilms' tumor gene, WT1, during differentiation of embryonal carcinoma and embryonic stem cells.
Scharnhorst V; Kranenburg O; van der Eb AJ; Jochemsen AG
Cell Growth Differ; 1997 Feb; 8(2):133-43. PubMed ID: 9040935
[TBL] [Abstract][Full Text] [Related]
16. A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein.
Madden SL; Cook DM; Rauscher FJ
Oncogene; 1993 Jul; 8(7):1713-20. PubMed ID: 8510918
[TBL] [Abstract][Full Text] [Related]
17. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
18. Development, characterization, and epitope mapping of a panel of twenty-four monoclonal antibodies specific for human inducible nitric oxide synthase.
Webber RJ; Rodriguez JG; Webber DS; Dunnebacke TH
Hybridoma (Larchmt); 2005 Feb; 24(1):6-13. PubMed ID: 15785204
[TBL] [Abstract][Full Text] [Related]
19. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
Kim JM; Hong Y; Semba K; Kim S
Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour.
Charles AK; Moore IE; Berry PJ
Histopathology; 1997 Apr; 30(4):312-4. PubMed ID: 9147076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
